Trial | NCT01518036  Report issue

Title

Use of Somatropin in Turner Syndrome
The Use of Norditropin® in Turner's Syndrome

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    somatropin ...

  • Study Participants

    57
This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.
Study Started
Sep 14
1987
Primary Completion
Apr 11
2004
Study Completion
Apr 11
2004
Last Update
Feb 28
2017

Drug somatropin

2.9 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached

Drug somatropin

4.3 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached

Low dose Experimental

High dose Experimental

Criteria 

Inclusion Criteria:

Turner Syndrome
Not previously treated with growth hormone or androgen
Well-documented height over the previous 12 months
Informed consent of parents (and child if appropriate)

Exclusion Criteria:

Growth hormone (GH) deficiency based on a GH stimulation test
No Results Posted